Literature DB >> 9293917

Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.

G Hu1, W Liu, J Mendelsohn, L M Ellis, R Radinsky, M Andreeff, A B Deisseroth.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGF-R) proteins are highly expressed in many tumors, including those of the cervix. We have observed previously that the introduction of a transcription unit containing an antisense sequence for the E6/E7 genes of human papillomavirus (HPV) 18, along with a transcription unit containing a sense complementary DNA sequence for the wild-type retinoblastoma (Rb) gene, decreased the growth of human cervical carcinoma HeLa cells (HPV 18 positive) both in vitro and in vivo. To clarify the regulatory mechanisms by which this reduction in cell proliferation occurred, we studied the expression of EGF-R proteins in these cells.
METHODS: Western blot and northern blot techniques were used to measure EGF-R expression, and a pulse-chase immunoprecipitation assay was used to measure the stability of EGF-R protein in HeLa cells and HeLa cells that had been transfected with the antisense E6/E7 or sense Rb sequences. Cell proliferation was measured by use of a tetrazolium-based colorimetric assay for numbers of viable cells.
RESULTS: The introduction of sense Rb or antisense E6/E7 transcription units or a combination of these two transcription units into HeLa cells dramatically decreased the level of EGF-R proteins in these cells; EGF-R levels were not affected at the transcriptional level but at the post-transcriptional level. Addition of the anti-EGF-R-specific monoclonal antibody 225mAb to HeLa cells caused 53% (95% confidence interval = 44%-62%) growth inhibition.
CONCLUSIONS: These results suggest that HeLa cervical carcinoma cells are dependent on EGF-R for proliferation and that changes in functional levels of the E6/E7 HPV proteins and endogenous Rb proteins may alter the growth rate of cervical cancer cell lines by reducing the stability of EGF-R at the post-transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293917     DOI: 10.1093/jnci/89.17.1271

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

3.  Anti-CD3/anti-epidermal growth factor receptor-bispecific antibody retargeting of lymphocytes against human neoplastic keratinocytes in an autologous organotypic culture model.

Authors:  Isabelle Renard; Delia Mezzanzanica; Silvana Canevari; Silvano Ferrini; Jacques Boniver; Philippe Delvenne; Nathalie Jacobs
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.

Authors:  John Farley; Michael W Sill; Michael Birrer; Joan Walker; Russell J Schilder; J Tate Thigpen; Robert L Coleman; Brigitte E Miller; Peter G Rose; Heather A Lankes
Journal:  Gynecol Oncol       Date:  2011-02-16       Impact factor: 5.482

5.  Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes.

Authors:  A Bheda; K E Creek; L Pirisi
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

6.  Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma.

Authors:  N Liu; T Furukawa; M Kobari; M S Tsao
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

7.  An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.

Authors:  Lixin Zhang; Yucheng Tang; Hakan Akbulut; Daniel Zelterman; Phyllis-Jean Linton; Albert B Deisseroth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-25       Impact factor: 11.205

8.  EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Authors:  K Iida; K Nakayama; M T Rahman; M Rahman; M Ishikawa; A Katagiri; S Yeasmin; Y Otsuki; H Kobayashi; S Nakayama; K Miyazaki
Journal:  Br J Cancer       Date:  2011-07-05       Impact factor: 7.640

9.  Molecular profiling of cervical cancer progression.

Authors:  T Hagemann; T Bozanovic; S Hooper; A Ljubic; V I F Slettenaar; J L Wilson; N Singh; S A Gayther; J H Shepherd; P O A Van Trappen
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

10.  Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

Authors:  N Giocanti; C Hennequin; D Rouillard; R Defrance; V Favaudon
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.